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HMGB1, composed of the A box, B box, and C tail domains, is a critical proinﬂammatory cytokine involved in diverse
inﬂammatorydiseases.TheBboxmediatesproinﬂammatoryactivity,whiletheAboxaloneactsasaspeciﬁcantagonistofHMGB1.
The C tail contributes to the spatial structure of A box and regulates HMGB1 DNA binding speciﬁcity. It is unknown whether the
C tail can enhance the anti-inﬂammatory eﬀect of A box. In this study, we generated fusion proteins consisting of the A box and C
tail,inwhichtheBboxwasdeletedandtheAboxandCtailwerelinkedeitherdirectlyorbytheﬂexiblelinkersequence(Gly4Ser)3.
In vitro and in vivo experiments showed that the two fusion proteins had a higher anti-inﬂammatory activity compared to the A
box alone. This suggests that the fused C tail enhances the anti-inﬂammatory eﬀect of the A box.
1.Introduction
High-mobility group box 1 (HMGB1) is an important
nonhistone nuclearprotein [1],butcanalsobereleasedfrom
the nucleus into the extracellular space, acting as a critical
proinﬂammatory cytokine in response to exogenous bacte-
rial products or endogenous inﬂammatory stimuli [2, 3].
Although originally deﬁned as a late mediator of endotoxin
lethality [2, 4], a recent report showed that HMGB1 was
elevated within six hours of traumatic injury in humans,
suggesting that it may be integral to the early inﬂammatory
response to trauma [5]. HMGB1 simulates the downstream
proinﬂammatory cascade responses by binding to three
receptors: Toll-like receptor 4 (TLR4), TLR2, and receptor
f o ra d v a n c e dg l y c a t i o ne n dp r o d u c t s( R A G E )[ 6]. Because
of its pivotal role in inﬂammatory pathogenesis as a late
and early proinﬂammatory cytokine, HMGB1 has become
an attractive target for the clinical management of sepsis and
certain infectious and inﬂammatory disorders [7, 8].
HMGB1 is highly conserved across species and is wildly
distributed in eukaryotic cells from yeast to human [9].
Human HMGB1, a 215-amino acid protein, contains three
major functional domains: the A box, the B box, and
the C-terminal acidic tail (C tail) [10, 11]. Structure-
function analyses reveal that the proinﬂammatory cytokine-
inducing capacity of HMGB1 localizes to the B box, with
the most signiﬁcant cytokine functionality mapping in the
ﬁrst 20 amino acid residues of this domain [12]. However,
the A box alone can competitively inhibit the binding of
HMGB1 to its receptors and attenuate the proinﬂammatory
eﬀect of the full length HMGB1 and the B box peptide.
The A box is thus considered a speciﬁc antagonist of
HMGB1 [13, 14]. Moreover, recent reports showed that
the C tail contributed to the spatial structure of both
A box and B box and regulated HMGB1 DNA binding
speciﬁcity [11, 15]. However, it is unknown whether the
C tail can enhance the anti-inﬂammatory activity of the A
box.2 Journal of Biomedicine and Biotechnology
The aim of this study was to identify whether the anti-
i n ﬂ a m m a t o r ya c t i v i t yo ft h eAb o xc o u l db ee n h a n c e d
by a fused C tail. We generated two fusion proteins
consisting of the A box and C tail, in which the B
box was deleted and the A box and C tail were linked
either directly or through the ﬂexible linker sequence,
(Gly4Ser)3. In vitro and in vivo experiments demonstrated
that the two fusion proteins, especially the (Gly4Ser)3-
linked protein, had a higher anti-inﬂammatory activity
compared to the A box alone, indicating that the fused
C tail enhances the anti-inﬂammatory eﬀect of the A
box. The fusion proteins composed of the A box and
C tail may have more potential clinical signiﬁcance for
the treatment of HMGB1-associated inﬂammatory dis-
eases.
2.MaterialsandMethods
2.1.PreparationofRecombinantHumanHMGB1(rHMGB1),
rHMGB1 A Box (A Box), and Control Protein Dihydrofolate
Reductase (DHFR). The three proteins were expressed in
Escherichia coli (E. coli) DH5α with a pQE-80L prokaryotic
expression vector (Qiagen, Germany) containing an N-
terminal 6×His tag-encoding sequence. The proteins were
puriﬁed using a Ni2+-nitrilotriacetic acid (Ni2+-NTA) chro-
matography kit (Qiagen, Germany) as previously described
[16]. Judging from SDS-PAGE gel results, the purity of the
three proteins was greater than 90%.
2.2. Cloning, Expression and Puriﬁcation of the Two Fusion
P r o t e i n sC o m p o s e do ft h eAB o xa n dCT a i l . The recombinant
proteins corresponding to the full-length human HMGB1 A
box fused with C tail directly (A box+C tail) and the A box
fused with C tail by a (Gly4Ser)3linker (A box+(Gly4Ser)3+C
tail) are depicted in Figure 1. The A box+C tail protein was
constructed by one-step opposite direction PCR (TaKaRa
MutanBest Kit, Japan) according to the manufacturer’s
instructions and using the oligonucleotides 5 -GAAGA-
GGAGGAAGATGAGGAAGAT-3  (forward primer) and 5 -
TGTCTCCCCTTTGGGAGGGATATA-3  (reverse primer)
and a full-length human HMGB1 cDNA cloned in pUC19
vector as a template. The resulting plasmid containing the
A box+C tail encoding fragment was named pUC19/A
box+C tail. The fragment encoding the A box+(Gly4Ser)3+C
tail protein was constructed by three rounds of one-step
opposite direction PCR. For the ﬁrst round of one-step
opposite direction PCR, the forward primer 5 -GGCGG-
AGGTGGATCAGAAGAGGAGGAAGATGAG-3  and the
reverse primer 5 -TGTCTCCCCTTTGGGAGGGATATA-
3  were used to amplify the plasmid pUC19/A box+C tail.
The resulting plasmid containing the A box+Gly4Ser+C tail-
encoding sequence was named pUC19/A box+Gly4Ser+C
tail. Similarly, the second and the third rounds of one-step
opposite direction PCR were done with the primers 5 -
GGAGGAGGCGGTTCGGGCGGAGGTGGATCAGAAGA-
G-3  (forward primer) and 5 -TGTCTCCCCTTTGGGAG-
GGATATA-3  (reverse primer) (for the second round of
PCR), and the primers 5 -GGCGGAGGTGGATCTGG-
AGGAGGCGGTTCGGGCGGA-3  (forwardprimer)and5 -
TGTCTCCCCTTTGGGAGGGATATA-3  (reverse primer)
(for the third round of PCR). Following the third round
of one-step opposite direction PCR, the plasmid containing
the A box+(Gly4Ser)3+C tail-encoding sequence was gen-
erated and named pUC19/A box+(Gly4Ser)3+C tail. After
sequencing, the fragments encoding the A box+C tail and
A box+(Gly4Ser)3+C tail proteins were excised from plas-
mids pUC19/A box+C tail and pUC19/A box+(Gly4Ser)3+C
tail, respectively, and were individually ligated into the
KpnI/HindIII cloning site of a pQE-80L prokaryotic expres-
sion vector. The two expression vectors were then individu-
ally transformed into E. coli DH5α and induced by isopropyl
β-D-1-thiogalactopyranoside(IPTG,Sigma, USA)toexpress
the corresponding proteins. Expression was veriﬁed by
western blot analysis using a mouse antihuman HMGB1
monoclonal antibody (Abnova, Taiwan) directed against
the A box. The expressed recombinant fusion proteins
were puriﬁed by the Ni2+-NTA chromatography kit under
normal condition and following the instructions of the
manufacturer. The purities of the proteins were analyzed by
SDS-PAGE.
2.3. Endotoxin Removal from Proteins. Endotoxin was
removed from all of the protein samples used in this study,
including rHMGB1, A box, DHFR, A box+C tail, and A
box+(Gly4Ser)3+C tail, by polymyxin B columns (Pierce,
USA) according to the manufacturer’s instructions. The LPS
content in the recombinant proteins was measured by the
chromogenic Limulus amebocyte lysate assay (BioWhittaker,
USA).
2.4. Cell Culture. THP-1 cells (American Type Culture
Collection) were cultured in RPMI 1640 medium (Gibco,
USA) supplemented with 10% fetal bovine serum (Gibco,
USA), penicillin (100U/mL), and streptomycin (100μg/mL)
(Gibco, USA) in a 37
◦C humidiﬁed incubator with 5% CO2
and 95% room air. For stimulation experiments, polymyxin
B was added to the cell culture medium at 6 units of
polymyxin B per pg of LPS. The amount of polymyxin B
used was suﬃcient to neutralize the remaining amount of
contaminating endotoxin [13].
2.5. Measurement of TNF-α and IL-6. TNF-α and IL-6
levels were determined by enzyme-linked immunosorbent
assay (ELISA) kits (R&D System, USA) according to the
instructions of the manufacturer. The concentrations of the
two cytokines were calculated with reference to standard
curves of puriﬁed recombinant TNF-α and IL-6 at various
dilutions.
2.6. Animal Experiments. Male BALB/c mice (20–22g) were
purchased from the Laboratory Animal Center of The
Third Military Medical University. The mice were housed
under standard temperature, light and dark cycles, and
manipulated according to the local conventions for the care
and use of laboratory animals (Chongqing, China).Journal of Biomedicine and Biotechnology 3
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Figure 1: Schematic representation of the C tail-fused A box proteins used in this work. Wild type human HMGB1 is composed of three
domains: the A box (amino acid residues 1–85), the B box (amino acid residues 88–162), and the C tail (amino acid residues 186–215). A
box+C tail: A box fused with C tail directly. A box+(Gly4Ser)3+C tail: A box fused with C tail via a (Gly4Ser)3 linker.
2.7. Serum Collection. BALB/c mice were injected i.p. with
LD75 doses of 15mg/kg LPS (Sigma, USA) as previously
described [12] and were treated at 0 and 12 hours after LPS
injection with A box, A box+C tail, A box+(Gly4Ser)3+C tail,
or DHFR control proteins (40nmol/mouse i.p.). The sera of
the mice were collected through orbital bleeding 6, 12 and 18
hours after LPS injection, respectively.
2.8. LPS Lethality. BALB/c mice, subjected to an LD75
doses of LPS as above, were treated at 0 and 12
hours after LPS administration with A box, A box+C
tail, A box+(Gly4Ser)3+C tail, or DHFR control proteins
(40nmol/mouse i.p.). Mortality was monitored for up to 10
days after the procedure to ensure no late death occurred.
2.9. Statistical Analysis. Data are presented as means ±
standard deviation. Statistical analysis was performed with
the SPSS13.0 software. Diﬀerences in TNF-α and IL-6 levels
between treatment groups were determined by one-way
ANOVA. Survival rates were analyzed by the Kaplan-Meier
method with comparisons between diﬀerent groups. A P
value less than .05 was considered statistically signiﬁcant.
3. Results
3.1. Preparation of Recombinant Proteins. The fusion pro-
teins A box+C tail and A box+(Gly4Ser)3+C tail were
successfully constructed and expressed in E. coli DH5α by
IPTG induction, and expression was conﬁrmed by west-
ern blot (Figure 2(a)). The two proteins were puriﬁed by
Ni2+-NTA chromatography, and their purities were greater
than 90% as judged by SDS-PAGE (Figure 2(b)). After
endotoxin was removed by polymyxin B columns, the
LPS content in rHMGB1, A box, DHFR, A box+C tail
and A box+(Gly4Ser)3+C tail was 1.09ng/mL, 1.08ng/mL,
1.54ng/mL, 1.06ng/mL, and 1.17ng/mL, respectively.
3.2. The C Tail-Fused A Box Proteins Inhibited HMGB1-
Induced TNF-αandIL-6ReleaseInVitroMoreEﬃcientlythan
A Box Alone. The levels of proinﬂammatory cytokines TNF-
α and IL-6 in THP-1 cell culture supernatant were measured
6 hours after rHMGB1 administration in the presence of
A box+C tail, A box+(Gly4Ser)3+C tail, A box or DHFR
control proteins. As shown in Figures 3(a) and 3(b),A
box, A box+C tail, and A box+(Gly4Ser)3+C tail inhibited
HMGB1-induced TNF-α and IL-6 release from THP-1 cells.
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Figure 2: Western blot and SDS-PAGE analysis of the C tail-
fused A box proteins. (a) Identiﬁcation of the two fusion proteins
expressed in E. coli DH5α by western blot using a mouse anti-
human HMGB1 monoclonal antibody directed against A box.
Lane 1:A box+C tail; Lane 2:A box+(Gly4Ser)3+C tail. (b) Purity
analysis of the two fusion proteins by SDS-PAGE. After puriﬁcation
by Ni2+-NTA chromatography, the purities of the two fusion
proteins were analyzed with SDS-PAGE. Equal amounts of purity
proteins(10μg)wereloadedinFigure 2(b),separatedby12%PAGE
gel electrophoresis. Lane 1:Molecular weight standards; Lane 2:A
box+C tail; Lane 3:A box+(Gly4Ser)3+C tail.
The two C tail-fused A box proteins were more eﬃcient
than A box alone, and the A box+(Gly4Ser)3+C tail had the
highest activity. These results indicated that the C tail-fused
A box proteins, especially A box+(Gly4Ser)3+C tail, had an
enhanced antiinﬂammatory eﬀect in vitro.
3.3. The C Tail-Fused A Box Proteins Had a Higher Anti-
Inﬂammatory Activity In Vivo Compared to A Box Alone.
TNF-α and IL-6 levels in the sera of the mice subjected
to endotoxemia were assayed by ELISA at 6, 12, and
1 8h o u r sa f t e rt r e a t m e n tw i t hAb o x ,Ab o x + Ct a i l ,A
box+(Gly4Ser)3+C or DHFR control proteins. As shown in
Figures 3(c) and 3(d), the A box and the two C tail-fused A4 Journal of Biomedicine and Biotechnology
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Figure 3: The C tail-fused A box could suppress TNF-α and IL-6 release in vitro and in vivo more eﬃciently than A box alone. (a) and (b)
The C tail-fused A box could inhibit HMGB1-induced TNF-α and IL-6 release in vitro more eﬃciently than A box alone. THP-1 cells in
96-well plates were treated with rHMGB1 (0.05μmol/L) and various concentrations of A box, A box+C tail, A box+(Gly4Ser)3+C tail, or
DHFR control proteins (as indicated) for 6 hours in the presence of polymyxin B (6 units per pg of LPS). The levels of TNF-α and IL-6 in the
cultured supernatants were measured by ELISA. Each experiment was performed in triplicate and repeated three times. (c) and (d) The C
tail-fused A box could reduce serum TNF-α and IL-6 levels in the mice subjected to endotoxemia more eﬃciently than A box alone. BALB/c
mice (5 mice/group), subjected to LD75 doses of LPS (15mg/kg), were treated at 0 and 12 hours after LPS injection with A box, A box+C
tail, A box+(Gly4Ser)3+C tail or DHFR control proteins (40 nmol per mouse). The sera of the mice were obtained from orbital blood 6, 12,
and 18 hours after LPS injection respectively. The serum levels of TNF-α and IL-6 were determined by ELISA. Each experiment was repeated
three times. The results showed that the A box alone and the two C tail-fused A box proteins could signiﬁcantly inhibit TNF-α and IL-6
release in vitro and in vivo. The A box+(Gly4Ser)3+C tail fusion protein had the most eﬃcient inhibitory activity, followed by the A box+C
tail fusion protein and the A box. Data shown are the means ± standard deviation and were analyzed with one-way ANOVA. a: P<. 05
versus DHFR; b: P<. 05 versus A box; c: P<. 05 versus A box+C tail.
box proteins signiﬁcantly reduced the serum TNF-α and IL-
6 levels in 6 and 18 hours. The potency of inhibitory activity
was in the order of A box+(Gly4Ser)3+C tail, A box+C tail,
and A box. But there were no inhibitory eﬀects in 12 hours.
Moreover, the LPS lethality assay showed that A box and
the two C tail-fused A box proteins signiﬁcantly prolonged
life time and improved the survival rates of LPS-induced
endotoxemia mice (Figure 4). The protective activity was in
the same order as above. These results indicated that the
C tail-fused A box proteins, especially A box+(Gly4Ser)3+C
tail, had an enhanced anti-inﬂammatory eﬀect in vivo.
4. Discussion
We have clearly demonstrated for the ﬁrst time in this study
that the in vitro and in vivo anti-inﬂammatory activity of
HMGB1A box wasenhanced whenfused withthe C tail,and
that the fusion protein containing a (Gly4Ser)3 linker had the
most anti-inﬂammatory eﬀect.
As a late and early proinﬂammatory cytokine, extra-
cellular HMGB1 has been found to play a pivotal role in
the pathogenesis of many acute and chronic inﬂammatory
diseases by binding to three receptors: TLR4, TLR2 andJournal of Biomedicine and Biotechnology 5
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Figure 4: The C tail-fused A box could more eﬀectively protect
against endotoxin lethality. BALB/c mice (20 mice/group), sub-
jected to LD75 doses of LPS, were treated at 0 and 12 hours after
LPS administration with A box, A box+C tail, A box+(Gly4Ser)3+C
tail, or DHFR control proteins (40nmol/mouse i.p.). Mortality was
monitoredforupto10days.Thesurvivalrateswereanalyzed bythe
Kaplan-Meier method with comparisons between diﬀerent groups.
The results showed that the A box alone and the two C tail-fused A
box proteins could signiﬁcantly prolong life time and improve the
survival rates of the mice (P<. 05). The A box+(Gly4Ser)3+C tail
proteinhadthemostprotectiveeﬀect,followedbyAbox+Ctailand
Ab o x( P<. 05).
RAGE [2, 6, 17, 18]. HMGB1 has a special structure-
functional characteristic in that the B box contains proin-
ﬂammatory activity and the A box alone can attenuate
the proinﬂammatory eﬀect of the full length HMGB1 and
the B box peptide. The C tail, consisting of 30 amino
acid residues, is a continuous array of aspartic acid and
glutamic acid residues. The phylogenetically conservative C
tail suggests that it has a very important role in the biological
activities of HMGB1 [11]. It has been reported that the
C tail can contribute to the spatial structure of both the
A box and B box, and can also regulate HMGB1 DNA
binding speciﬁcity [11, 15]. However, it is not clear whether
the C tail can enhance the anti-inﬂammatory activity of
the A box. To address this question, we generated two C
tail-fused A box proteins, in which the B box was deleted
and the A box was fused with C tail either directly or
linked by a (Gly4Ser)3 sequence. The in vitro and in vivo
anti-inﬂammatory assays demonstrated that the two novel
fusion proteins could reduce proinﬂammatory cytokine
(TNF-α and IL-6) release and protect against endotoxin
lethality more eﬀectively than A box alone, indicating that
the C tail enhances the anti-inﬂammatory activity of A
box.
(Gly4Ser)3 is a ﬂexible linker that is commonly used in
the construction of single-chain antibody fragments [19]. It
can help form the spatial structure of domains on both sides
without interfering with the function of the recombinant
proteins, and can even contribute to the activity of the
molecules. Our results showed that the C tail-fused A
box protein containing the (Gly4Ser)3 linker had a higher
anti-inﬂammatory activity than the protein fused directly,
suggesting that the linker sequence might enhance the
anti-inﬂammatory function of the fusion protein to some
extent.
Macrophages and monocytes have a central role in coor-
dinating responses to injury and infection. TNF-α is one of
the earliest cytokines released by activated macrophages and
plays an important role in the pathogenesis of inﬂammation
and endotoxic shock. IL-6 is a very important monocyte-
derived cytokine. HMGB1, a key proinﬂammatory factor, is
nearly as potent as LPS in stimulating downstream cytokine
synthesis in monocytes and macrophages. HMGB1 partici-
pates in “cross-talk” for the propagation and ampliﬁcation
of downstream proinﬂammatory cascade responses. TNF-α
and IL-6 are two major HMGB1-stimulated cytokines [2,
20]. Thus, in this study, these two cytokines were measured
to evaluate the anti-inﬂammatory activity of the HMGB1
fragment proteins.
The murine endotoxemia model is commonly used
in researches of HMGB1 inﬂammatory activity [2, 13].
In this study, the LPS-induced mice endotoxemia model
was established to evaluate the in vivo anti-inﬂammatory
activity and the endotoxin lethality protective eﬀect of the
HMGB1 fragment proteins. Both LPS and HMGB1 bind
TLR4 to stimulate downstream proinﬂammatory responses.
Therefore,aside from competitively inhibiting the binding of
HMGB1 to its receptors, the A box and C tail-fused A box
proteins may exert their in vivo anti-inﬂammatory eﬀect and
LPS-lethality protective function by blocking the binding of
LPS to TLR4.
Results from this study may have therapeutic implica-
tions. As a speciﬁc antagonist of HMGB1, the A box has
recently been suggested to be a potential anti-inﬂammatory
agent [13]. Our results showed that the fused C tail could
enhance the anti-inﬂammatory activity of the A box, which
suggests that the C tail-fused A box proteins, especially the
(Gly4Ser)3-linked fusion protein, may have more potential
clinical signiﬁcance for the treatment of HMGB1-associated
inﬂammatory diseases than the A box alone. More studies
are required to uncover the molecular mechanism by which
the fused C tail enhances the anti-inﬂammatory activity of A
box.
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